Nurix Therapeutics Inc

NASDAQ:NRIX   3:59:51 PM EDT
29.09
+0.87 (+3.08%)
Earnings Announcements

Nurix Therapeutics Says Collaboration Revenue For Three Months Ended August 31, 2021 Was $10.3 Million Versus$4.1 Mln For Three Months Ended August 31, 2020

Published: 10/14/2021 21:58 GMT
Nurix Therapeutics Inc (NRIX) - Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update.
Q3 Loss per Share $0.65.
Q3 Earnings per Share Estimate $-0.63 -- Refinitiv Ibes Data (analyst estimates).
Nurix Therapeutics - Collaboration Revenue for Three Months Ended August 31, 2021 Was $10.3 Million Versus$4.1 Million for Three Months Ended August 31, 2020.
Revenue is expected to be $13.65 Million
Adjusted EPS is expected to be -$0.67

Next Quarter Revenue Guidance is expected to be $8.69 Million
Next Quarter EPS Guidance is expected to be -$0.84

More details on our Analysts Page.